Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off-label in Switzerland and Australia. We investigated outcomes in association with clinicopathological features and expression of programmed death li...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2018-11, Vol.13 (11), p.1784-1791
Main Authors: Metaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia A., Klingbiel, Dirk, Kao, Steven, Schmid, Sabine, Nowak, Anna K., Gautschi, Oliver, Bartnick, Tammo, Hughes, Brett G., Bouchaab, Hasna, Rothschild, Sacha I., Pavlakis, Nick, Wolleb, Sibylle, Petrausch, Ulf, O'Byrne, Kenneth, Froesch, Patrizia, Löffler-Baumann, Melanie, Pratsch-Peter, Susanne, Russell, Prudence, Mingrone, Walter, Savic, Spasenija, Thapa, Bibhusal, Früh, Martin, Pless, Miklos, von Moos, Roger, John, Thomas
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Female
Humans
Immunotherapy
Immunotherapy - methods
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - pathology
Male
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - immunology
Mesothelioma - pathology
Mesothelioma, Malignant
Middle Aged
PD-1
Pembrolizumab
Pleural Neoplasms - drug therapy
Pleural Neoplasms - immunology
Pleural Neoplasms - pathology
Second-line therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off-label in Switzerland and Australia. We investigated outcomes in association with clinicopathological features and expression of programmed death ligand 1 (PD-L1). Registry data in Australia and Switzerland were pooled. Patient characteristics, including age, sex, histological subtype, and previous treatments were captured. Outcomes were assessed locally. PD-L1 expression was categorized as negative (
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2018.08.007